{"url_path":"/sec/ndra/8-k/2026-06-25/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 ** **Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-25","source_url":"https://www.sec.gov/Archives/edgar/data/1681682/0001213900-26-071804-index.html","accession_number":"0001213900-26-071804","cik":"0001681682","ticker":"NDRA","issuer_name":"ENDRA Life Sciences Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1681682/0001213900-26-071804-index.html","primary_entity_key":"0001681682","primary_entity_name":"ENDRA Life Sciences Inc."},"word_count":143,"has_tables":true,"body_markdown":"**Item 7.01** **Regulation FD Disclosure.** \n\n \n\nOn June 25, 2026, ENDRA Life Sciences Inc. (the\n“Company”) issued a press release announcing a proposed merger of its subsidiary with Noble Africa LLC, a wholly-owned subsidiary\nof ASP Isotopes, Inc. and intermediate holding company for Renergen Limited.\n\n \n\nA copy of the press release is included as Exhibit\n99.1 hereto and is incorporated herein by reference.\n\n \n\nThe information under this Item 7.01,\nincluding Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of\n1934, as amended, (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed\nto be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except\nas shall be expressly set forth by specific reference in such filing."}